Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-21298
J Neurochem 1994 May 01;625:1790-4. doi: 10.1046/j.1471-4159.1994.62051790.x.
Show Gene links Show Anatomy links

beta-Lumicolchicine interacts with the benzodiazepine binding site to potentiate GABAA receptor-mediated currents.

Mihic SJ , Whatley VJ , McQuilkin SJ , Harris RA .


???displayArticle.abstract???
An analogue of colchicine, beta-lumicolchicine, does not bind tubulin or disrupt microtubules. However, this compound is not pharmacologically completely inactive. beta-Lumicolchicine was found to competitively inhibit [3H]flunitrazepam binding and to enhance muscimol-stimulated 36Cl- uptake in mouse cerebral cortical microsacs. It also markedly potentiated GABA responses in Xenopus oocytes expressing human alpha 1 beta 2 gamma 2S, but not alpha 1 beta 2, GABAA receptor subunits; this potentiation was reversed by the benzodiazepine receptor antagonist flumazenil. These results strongly suggest a direct effect of beta-lumicolchicine on the GABAA receptor/chloride channel complex and caution that it possesses pharmacological effects, despite its inability to disrupt microtubules. Furthermore, beta-lumicolchicine is structurally unrelated to benzodiazepines or quinolines and may provide a novel approach to the synthesis of ligands for this receptor.

???displayArticle.pubmedLink??? 8158128
???displayArticle.link??? J Neurochem
???displayArticle.grants??? [+]

Species referenced: Xenopus laevis
Genes referenced: gabarap